SWK_logo_L.jpg

 

SWK Holdings Corporation Announces 2017 First Quarter

Financial Results

 

·Total revenues of approximately $14.9 million for the first quarter of 2017 compared to $5.2 million for the first quarter of 2016.

 

·Net income attributable to SWK Shareholders of $5.2 million, or $0.40 per share, and non-GAAP Adjusted net income of $9.4 million, or $0.72 per share for the first quarter of 2017.

 

·Book value of $16.22 per share as of March 31, 2017 vs. $15.68 as of December 31, 2016.

 

Dallas, TX, May 10, 2017 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its first quarter 2017 financial results.

 

First Quarter 2017 Highlights:

 

·Reported total revenues of approximately $14.9 million for the quarter, compared to $5.2 million for the first quarter of 2016.
·Reported adjusted net income of approximately $9.4 million, or $0.72 per diluted share, for the quarter, as compared to $3.1 million, or $0.24 per diluted share, for the first quarter of 2016.
·Total income producing assets (defined as finance receivables, marketable securities and investment in unconsolidated subsidiaries less non-controlling interests) were approximately $135.1 million as of March 31, 2017, compared to $132.2 million as of December 31, 2016.

 

“We are pleased with the portfolio’s performance this quarter as things progressed in line with our expectations,” stated Winston Black, Chief Executive Officer of SWK. “The sale of InnoPran XL this quarter marked SWK’s ninth portfolio position exit since we launched the specialty finance business in 2012. The cumulative positive returns we have earned on our exits, including the challenges faced in 2015, demonstrate the attractiveness of the life science specialty finance business. We remain excited to deploy additional capital into our future pipeline opportunities.”

 

Note:

 

·All references to growth rate percentages and shares compare the results of the period to those of the prior year comparable period.

 

·The Company reports its financial results in accordance with Generally Accepted Accounting Principles in the U.S. (“GAAP”). However, management believes that certain non-GAAP financial measures provide users with additional meaningful financial information that should be considered when assessing the Company’s ongoing performance. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company’s reported results prepared in accordance with GAAP. The Company’s non-GAAP financial information does not represent a comprehensive basis of accounting. Management also uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company’s performance.

 

·Non-GAAP Adjusted net income and its components and Non-GAAP Adjusted basic and diluted EPS are not, and should not be viewed as, substitutes for GAAP net income and its components and basic and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that these are Non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted net income and its components (unlike U.S. GAAP net income and its components) may not be comparable to the calculation of similar measures of other companies.

 

 
 

Portfolio Overview

 

As of March 31, 2017, the Company’s total income producing assets were approximately $135.1 million as compared to $132.2 million as of December 31, 2016.

 

(in thousands)  March 31,  December 31,
   2017  2016
       
Finance receivables  $130,824   $126,366 
Marketable investments   4,315    2,621 
Investment in unconsolidated entity   —      6,985 
Less non-controlling interest   —      (3,756)
Total income producing assets  $135,139   $132,216 

 

As of May 10, 2017, the Company and its partners have executed transactions with 25 different parties under its specialty finance strategy, funding $322 million in various financial products across the life science sector. At the end of the first quarter, the weighted average projected effective yield of the finance receivables portfolio was 14.7%. The projected effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies, if all payments are received pursuant to the terms of the finance receivables.

 

Results of Operations

 

Revenues

 

SWK generated revenues of $14.9 million for the three months ended March 31, 2017, driven primarily by $10.2 million in income related to our investment in an unconsolidated partnership and $4.7 million in interest and fees earned on our finance receivables. SWK generated revenues of $5.2 million for the three months ended March 31, 2016, driven primarily by $3.6 million in interest and fees earned on finance receivables and marketable securities, and $1.7 million in income related to our investment in an unconsolidated partnership. The increase in revenue is primarily driven by the net proceeds received related to our investment in an unconsolidated entity, which on February 23, 2017 transacted to sell its U.S. marketing rights to its underlying intellectual property. The increase in finance receivable interest was due to six new investments funded in the second through fourth quarters of 2016.

 

Impairment Expense

 

SWK did not recognize any security impairment expense during the three months ended March 31, 2017, as compared to a $0.3 million security impairment expense for the three months ended March 31, 2016.

 

General and Administrative

 

General and administrative expenses consist primarily of compensation, stock-based compensation and related costs for management, staff, Board of Directors, legal and audit expenses, and corporate governance. General and administrative expenses decreased to $0.7 million for the three months ended March 31, 2017 from $0.9 million for the three months ended March 31, 2016, due to a decrease in both cash-based and stock-based compensation.

 

 2 
 

Other Income (Expense)

 

Other income (expense) for the three months ended March 31, 2017, reflected a net fair market value loss of $0.5 million on our warrant derivatives and a $0.2 million realized gain on the sale of available-for-sale equity securities.

Other income (expense), net for the three months ended March 31, 2016 reflected a net fair market value loss of $30 thousand.

 

Income Tax Expense

 

SWK has incurred net operating losses on a consolidated basis for all years from inception through 2012. Accordingly, the Company has historically recorded a valuation for the full amount of gross deferred tax assets, as the future realization of the tax benefit was not “currently more likely than not.” SWK believes that it is more likely than not that the Company will be able to realize approximately $34.8 million benefit of the U.S. federal and state deferred tax assets in the future.

 

As of March 31, 2017, the Company had NOLs for federal income tax purposes of $404.0 million. The federal net operating loss carryforwards if not offset against future income, will expire by 2032, with the majority expiring by 2021. We recognized $3.7 million of income tax expense for the three months ended March 31, 2017. No income tax expense was recognized for the three months ended March 31, 2016. SWK also had federal research credit carryforwards of $2.7 million. The federal research credits will expire by 2029.

 

Liquidity and Capital Resources

 

As of March 31, 2017, SWK had $40.5 million in cash and cash equivalents, compared to $32.2 million in cash and cash equivalents as of December 31, 2016. The primary driver of the net increase in the Company’s cash balance was the net proceeds of $8.0 million received related to its investment in an unconsolidated entity. At quarter’s end SWK had $8.1 million of unfunded commitments outstanding.

 

Adjusted Net Income

 

Net income in accordance with GAAP for the three month period ending March 31, 2017 was $10.3 million, and net income attributable to SWK Stockholders in accordance with GAAP for the three month period ending March 31, 2017, was $5.2 million, or $0.40 per diluted share. The table below eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and SWK’s warrant liability. The following tables provide a reconciliation of SWK’s reported (GAAP) income before provision for income tax to SWK’s adjusted net income attributable to SWK Holdings Corporation stockholders (Non-GAAP) for the three months ended March 31, 2017 and ended March 31, 2016:

 

(in thousands, except per share data)  Quarter Ended March 31,
   2017  2016
Consolidated net income  $10,268   $3,938 
Plus: income tax expense   3,706    —   
Plus: loss on fair market value of warrants   472    30 
Adjusted income before provision for income tax   14,446    3,968 
Adjusted provision for income taxes   —      —   
Non-GAAP consolidated net income   14,446    3,968 
Non-GAAP net income attributable to non-controlling interest   5,032    842 
Non-GAAP net income attributable to SWK Holdings Corporation Stockholders  $9,414   $3,126 
           
Adjusted basic income per share  $0.72   $0.24 
Adjusted diluted income per share  $0.72   $0.24 

 

In the presentation above, management has eliminated the following non-cash items: (i) fair-market value of warrants as mark to market changes are non-cash, and (ii) income taxes as the Company has substantial net operating losses to offset against future income.

 

 3 
 

About SWK Holdings Corporation

 

SWK Holdings Corporation is a specialized finance company with a focus on the global healthcare sector. SWK partners with ethical product marketers and royalty holders to provide flexible financing solutions at an attractive cost of capital to create long-term value for both SWK’s business partners and its investors. SWK believes its financing structures achieve an optimal partnership for companies, institutions and inventors seeking capital for expansion or capital and estate planning by allowing its partners to monetize future cash flow with minimal dilution to their equity stakes. Additional information on the life science finance market is available on the Company’s website at www.swkhold.com.

 

Safe Harbor Statement

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect SWK’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in SWK’s Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company’s actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

 4 
 

SWK HOLDINGS CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands, except par value and share data)

Derived from unaudited financial statements

 

  

March 31,

2017

 

December 31,

2016

ASSETS          
Cash and cash equivalents  $40,514   $32,182 
Accounts receivable   1,142    1,054 
Finance receivables   130,824    126,366 
Marketable investments   4,315    2,621 
Investment in unconsolidated entity   —      6,985 
Deferred tax asset   34,765    38,471 
Warrant assets   539    1,013 
Other assets   258    240 
Total assets  $212,357   $208,932 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Accounts payable and accrued liabilities  $730   $682 
Warrant liability   187    189 
Total liabilities   917    871 
           
Stockholders’ equity:          
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding   —      —   
Common stock, $0.001 par value; 250,000,000 shares authorized; 13,150,220, and 13,144,292 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively   13    13 
Additional paid-in capital   4,433,368    4,433,289 
Accumulated deficit   (4,223,674)   (4,228,910)
Accumulated other comprehensive income (loss)   1,733    (87)
Total SWK Holdings Corporation stockholders’ equity   211,440    204,305 
Non-controlling interests in consolidated entities   —      3,756 
Total stockholders’ equity   211,440    208,061 
Total liabilities and stockholders’ equity  $212,357   $208,932 

 

 5 
 

SWK HOLDINGS CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

Derived from unaudited financial statements

 

   Three Months Ended March 31,
   2017  2016
Revenues      
Finance receivable interest income, including fees  $4,656   $3,470 
Marketable investments interest income   —      92 
Income related to investments in unconsolidated entity   10,204    1,659 
Other   4    15 
Total revenues   14,864    5,236 
Costs and expenses:          
Impairment expense   —      339 
General and administrative   661    929 
Total costs and expenses   661    1,268 
Other income (expense), net          
Unrealized net loss on derivatives   (472)   (30)
Gain on sale of marketable securities   243    —   
Income before provision for income taxes   13,974    3,938 
Provision for income taxes   3,706    —   
Consolidated net income   10,268    3,938 
Net income attributable to non-controlling interests   5,032    842 
Net income attributable to SWK Holdings Corporation Stockholders  $5,236   $3,096 
Net income per share attributable to SWK Holdings Corporation Stockholders:          
Basic  $0.40   $0.24 
Diluted  $0.40   $0.24 
Weighted Average Shares:          
Basic   13,144    13,117 
Diluted   13,147    13,132 

 

 6 
 

SWK HOLDINGS CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Derived from unaudited financial statements

 

   Three Months Ended March 31,
   2017  2016
Cash flows from operating activities:          
Consolidated net income  $10,268   $3,938 
Adjustments to reconcile net income to net cash provided by operating activities:          
Income from investment in unconsolidated entity   (10,204)   (1,659)
Impairment expense   —      339 
Deferred income taxes   3,706    —   
Change in fair value of warrants   472    30 
Gain on sale of marketable securities   (243)   —   
Loan discount amortization and fee accretion   (568)   (908)
Interest paid-in-kind   (383)   —   
Stock-based compensation   78    106 
Other   4    3 
Changes in operating assets and liabilities:          
Accounts receivable   (88)   (145)
Other assets   (112)   327 
Accounts payable and other liabilities   48    298 
Net cash provided by operating activities   2,978    2,329 
           
Cash flows from investing activities:          
Cash distributions from investment in unconsolidated entity   17,189    1,910 
Proceeds from sale of available-for-sale marketable securities   345    —   
Marketable investment principal payment   24    —   
Investment in finance receivables   (3,638)   (3,535)
Repayment of finance receivables   225    14,183 
Purchases of property and equipment   (3)   (3)
Net cash provided by investing activities   14,142    12,555 
           
Cash flows from financing activities:          
Distribution to non-controlling interests   (8,788)   (977)
Net cash used in financing activities   (8,788)   (977)
           
Net increase in cash and cash equivalents   8,332    13,907 
Cash and cash equivalents at beginning of period   32,182    47,287 
Cash and cash equivalents at end of period  $40,514   $61,194 

 

CONTACT: SWK Investor Relations at (972) 687-7250 or investor.relations@swkhold.com.

 

# # #

 

 7 


The following information was filed by Swk Holdings Corp (SWKH) on Thursday, May 11, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Swk Holdings Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Swk Holdings Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account